Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: A Cochrane systematic review

BJU International

Volumn 116, Issue 1, 2015, Pages 30-36

  Kunath, Frank ^a,b,c   Grobe, Henrik R ^b   Rücker, Gerta ^b   Motschall, Edith ^b   Antes, Gerd ^b   Dahm, Philipp ^d   Wullich, Bernd ^a,c   Meerpohl, Joerg J ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UroEvidence   (Germany)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

androgen ablation; antiandrogens; prostate cancer; randomized controlled trials

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; TRIPTORELIN; GONADORELIN RECEPTOR;

ABDOMINAL PAIN; BACKACHE; BIOCHEMICAL PROGRESSION; BONE PAIN; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CASTRATION; CLINICAL PROGRESSION; COMPARATIVE EFFECTIVENESS; DRUG FATALITY; DRUG MEGADOSE; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; MASTALGIA; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIC PAIN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DISCONTINUATION; TREATMENT FAILURE; AGONISTS; DISEASE FREE SURVIVAL; MALE; MORTALITY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, LHRH; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84933670789     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13026     Document Type: Review

References (29)

1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD,. Guidelines on Prostate Cancer. European Association of Urology, 2013. Available at: www.uroweb.org/gls/pdf/09-Prostate-Cancer-LR.pdf. Accessed 30 August 2013
2. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77
3. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605
4. Iversen P,. Antiandrogen monotherapy: indications and results. Urology 2002; 60 (3 Suppl 1): 64-71
5. Kunath F, Grobe HR, Rücker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev 2014; 6: CD009266.
6. Higgins JPT, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In, Higgins JPT, Green S, eds, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org
7. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012
8. Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34
9. Williamson PR, Smith CT, Hutton JL, Marson AG,. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002; 21: 3337-51
10. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60
12. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-94
13. Schünemann HJ, Oxman AD, Vist GE, et al. Chapter 12: Interpreting results and drawing conclusions. In, Higgins JPT, Green S, eds, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org
14. Boccon-Gibod L, Fournier G, Bottet P, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32: 391-5
15. Dockery F, Bulpitt CJ, Agarwal S, et al. Anti-androgens increase N-Terminal pro-BNP in men with prostate cancer. Clin Endocrinol (Oxf) 2008; 68: 59-65
16. Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C,. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl 2009; 30: 410-5
17. Sciarra A, Di Silverio F,. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology 2004; 63: 523-7
18. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S,. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272-6
19. Pirl WF, Greer JA, Goode M, Smith MR,. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology 2008; 17: 148-53
20. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS,. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546-53
21. Bales GT, Chodak GW,. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47 (1A Suppl): 38-43
22. Iversen P, Tveter K, Varenhorst E,. Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 1996; 30: 93-8
23. Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F,. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol 1995; 28: 215-22
24. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT,. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46: 849-55
25. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389-96
26. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82
27. Tyrrell CJ, Blake GM, Iversen P, Kaisary AV, Melezinek I,. The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol 2003; 21: 37-42
28. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56
29. Tyrrell CJ, Iversen P, Tammela T, et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006; 98: 563-72 Erratum in: BJU Int 2006; 98(3):572.